



## **CURRICULUM VITAE**

**Yvette Bren-Mattison, PhD**

|                                |                                                                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Date:</b>                   | April 23, 2026                                                                                                                                                  |
| <b>School:</b>                 | School of Medicine                                                                                                                                              |
| <b>Department/Program:</b>     | Surgery / Surgical Oncology                                                                                                                                     |
| <b>Current Title:</b>          | Assistant Professor - Research                                                                                                                                  |
| <b>Business Address:</b>       | LSU Health, School of Medicine<br>Department of Surgery<br>Division of Surgical Oncology<br>2021 Perdido Street, 8 <sup>th</sup> Floor<br>New Orleans, LA 70112 |
| <b>Business Telephone:</b>     | (504) 504-5735                                                                                                                                                  |
| <b>Business email Address:</b> | ymatti@lsuhsc.edu                                                                                                                                               |

|                                             |                                       |
|---------------------------------------------|---------------------------------------|
| <b>Initial Appointment at LSUHSC Date:</b>  | August 1, 2019 (Research Associate 3) |
| <b>Current Academic Rank:</b>               | Assistant Professor - Research        |
| <b>Date of Appointment to Current Rank:</b> | September 21, 2022                    |

### **Education**

#### **Undergraduate:**

|               |                                                                           |
|---------------|---------------------------------------------------------------------------|
| December 1994 | B.S., Biochemistry: University of New York @ Stony Brook, Stony Brook, NY |
|---------------|---------------------------------------------------------------------------|

#### **Graduate/medical:**

|          |                                                                                                 |
|----------|-------------------------------------------------------------------------------------------------|
| May 2002 | PhD, Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, CO |
|----------|-------------------------------------------------------------------------------------------------|

#### **Post-doctoral fellowships:**

|          |                                                                     |
|----------|---------------------------------------------------------------------|
| May 2003 | Research Fellowship, University of Colorado at Boulder, Boulder, CO |
|----------|---------------------------------------------------------------------|

|               |                                                                                        |
|---------------|----------------------------------------------------------------------------------------|
| December 2006 | Research Fellowship Anschutz Medical Campus, University of Colorado Denver, Denver, CO |
|---------------|----------------------------------------------------------------------------------------|

## **Academic, Professional, and Research Appointments**

### **Academic Appointments:**

- 2019-2022     Research Associate 3, LSU Health Sciences Center, School of Medicine, New Orleans, LA
- 2022-present   Assistant Professor – Research, LSU Health Sciences Center, School of Medicine, New Orleans, LA
- 2022-present   Director of Clinical Research Rare Cancer Program, LSU Health Sciences Center, School of Medicine, New Orleans, LA

### **Professional Appointments:**

- 2006-2008     Senior Scientist, Sporian Microsystems, Inc, Lafayette, CO
- 2008-2010     Senior Scientist, MBC Pharma Inc., Denver, CO
- 2011-2019     Contributing Medical Writer, Scitable.com Nature
- 2011-2019     Consultant, BioMed Bridge, LLC.

## **TEACHING EXPERIENCE AND RESPONSIBILITIES**

### **Formal Course Responsibilities:**

As part of my doctoral training, I taught undergraduate laboratory courses and helped to train the next generation of scientists and physicians.

- 1998-2000     Teaching Assistant, MCDB 1161: Genomics Laboratory 1, University of Colorado at Boulder
- 1998-2000     Teaching Assistant, Modular Laboratory of Molecular Biology Skills, University of Colorado at Boulder

### **Teaching Summary Table**

| <b>Teaching Type or Format</b> | <b>Hours/year*</b> | <b>Taught individually or as part of a team</b> | <b>Recorded or Live</b> |
|--------------------------------|--------------------|-------------------------------------------------|-------------------------|
| Lab instruction                | 128                | Individually                                    | Live                    |

\*Average since the last promotion

## Departmental/Interdisciplinary Teaching Conferences

2025 – present      Organizer/lead, Rare Cancer Clinical Trial Board, LSUHSC

## RESEARCH AND SCHOLARSHIP

### Grants and Contracts

#### Funded:

|              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2022-present | <p><u>A Phase II Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMATATE in PRRT Naïve Subjects with Somatostatin Receptor Expressing Neuroendocrine Tumors.</u></p> <p>Principal Investigator name: Mary Maluccio<br/>Role: Sub-I<br/>Award Type and Number: Industry<br/>Funding Agency/Institution: Orano Med<br/>Project Period: 5 years<br/>Percent Effort: 15%<br/>Amount: <b>\$1,661,402.89</b></p>                                                           |
| 2022-present | <p><u>Randomized, Multicenter, Open Label, Active Controlled, Phase III Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot versus LAR or Lanreotide ATG in Patients with Gastroenteropancreatic Neuroendocrine Tumors.</u></p> <p>Principal Investigator name: Mary Maluccio<br/>Role: Sub-I<br/>Award Type and Number: Industry<br/>Funding Agency/Institution: Camurus AB<br/>Project Period: 5 years<br/>Percent Effort: 10%<br/>Amount: <b>\$ 268,529.86</b></p> |
| 2023-present | <p><u>A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.</u></p> <p>Principal Investigator name: Mary Maluccio<br/>Role: Sub-I<br/>Award Type and Number: Industry<br/>Funding Agency/Institution: Crinetix Pharmaceuticals<br/>Project Period: 3 years<br/>Percent Effort: 10%<br/>Amount: <b>\$ 319,373.13</b></p>                                                             |

- 2023-present      Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)  
Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: RayzeBio Pharmaceuticals  
Project Period:4 years  
Percent Effort: 15%  
Amount: **\$ 1,219,954.35**
- 2025-present      CRN00808-12. A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors  
Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: Crinetics Pharmaceuticals  
Project Period:3 years  
Percent Effort: 10%  
Amount: **\$ 443,714.46**
- 2025-present      A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET (NETTER-3).  
Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: Novartis Pharmaceuticals  
Project Period:4 years  
Percent Effort: 10%  
Amount: **\$ 371,433.53**
- 2025-present      A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2 Expressing Solid Tumors  
Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: Crinetics Pharmaceuticals

Project Period: 3 years  
Percent Effort: 10%  
Amount: **\$ 249,194.74**

2025-present

A Phase 2/3, Multicenter, Randomized Open-label Study of Zanzalintinib vs Everolimus in Participants with Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: Exelixis Pharmaceuticals  
Project Period: 4 years  
Percent Effort: 10%  
Amount: **\$ \$678,974.30**

**Currently In start-up (under contract negotiations):**

Project name: A Randomized Phase III Trial to Compare the Efficacy and Safety of 212Pb-DOTAMATATE therapy to the efficacy and safety of LUTATHERA® in Adults with Advanced Somatostatin Receptor-positive (SSTR+), Grade 1 to 3 well-differentiated GEP-NETs.  
Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: Orano Med  
Project Period: 5 years  
Percent Effort: 15%  
Amount: Under negotiations

Project name: A Phase I/IIa First-in-Human Study of [212Pb]VMT- $\alpha$ -NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors  
Principal Investigator name: Mary Maluccio  
Role: Sub-I  
Award Type and Number: Industry  
Funding Agency/Institution: Perspective Pharmaceuticals  
Project Period: 5 years  
Percent Effort: 15%  
Amount: Under negotiations

Project name: A Pilot Study to Test the Feasibility of Using a PET-probe with 64Cu-DOTATATE to Detect and Localize Neuroendocrine Tumors Intraoperatively  
Principal Investigator name: Mary Maluccio  
Role: Sub-I/lead author  
Award Type and Number: Investigator-initiated Trial

Funding Agency/Institution: Curium Pharmaceuticals  
Project Period: 5 years  
Percent Effort: 20%  
Amount: Under negotiations

**Currently Under Review:**

Project name: Omic signatures and machine learning to predict response to PRRT

Principal Investigator name: Mary Maluccio  
Role: Co-PI  
Award Type and Number: Investigator-initiated Trial  
Funding Agency/Institution: Neuroendocrine Tumor Research Fund  
Project Period: 2 years  
Percent Effort: 5%

Project name: Whole genome sequencing for response to anti-angiogenetic agents in neuroendocrine neoplasms

Principal Investigator name: James Skill  
Role: Co-PI  
Award Type and Number: Pilot Award  
Funding Agency/Institution: Neuroendocrine Tumor Research Fund  
Project Period: 2 years  
Percent Effort: 5%

Project name: <sup>31</sup>P MRS Signatures and Hepatocellular Carcinoma - Stratification of patients for chemoprevention

Principal Investigator name: James Skill  
Role: Co-PI  
Award Type and Number: Pilot Award  
Funding Agency/Institution: LSU - LCMC Health Cancer Center— Innovative and Catalytic Cancer Research  
Project Period: 2 years  
Percent Effort: 5%

**Recent non-funded applications:**

Project name: Utilization of metabolomics to optimize nutrition in patients with liver disease.  
Department of Defense Discovery Award W81XWH-20-PRMRP-DA  
Role: Co-Investigator

Project name: Translational Research Access Disparities for Rare Cancers.  
NIH RFA-TR-20-001 R01

Role: Co-Investigator

Project name: Community partnership to study clinical trial access disparities for rare cancers  
Louisiana Clinical and Translational Science Center (NIH)  
Role: Co-Investigator

Project name: Monitoring and targeting CD73 for gastrointestinal neuroendocrine neoplasms  
Neuroendocrine Tumor Research Fund (NETRF)  
Role: Co-Investigator

Project name: Clinical Trial Readiness for Rare Neuroendocrine Tumors  
NIH R21 PAR-22-10  
Role: Co-Investigator

### **Major Area of Research Interest:**

My research focuses primarily on rare cancers, specifically Neuroendocrine cancer. As the Director of Clinical Research for the Rare Cancer Program, I have built a thriving clinical research program which offers patients with Neuroendocrine cancer access to cutting-edge therapies that were not previously available in the state of Louisiana. Additionally, I have developed collaborations with both intramural and extramural academic research partners to pursue translational research and develop the basis for investigator-initiated trial proposals.

### **Journal Publications**

#### **Refereed**

##### **Published:**

1. **Bren-Mattison, Y.** & Olwin, B.B. (2002) Sonic Hedgehog Inhibits the Terminal Differentiation of Limb Myoblasts Committed to the Slow Muscle Lineage. *Developmental Biology*. 242: 103-148.
2. **Bren-Mattison, Y.**, Van Putten V., Chan D., Winn R., Geraci M.W., & Nemenoff R. A. (2005) Peroxisome proliferator-activated receptor-  $\gamma$  (PPAR- $\gamma$ ) inhibits tumorigenesis by reversing the undifferentiated phenotype of Metastatic non-small-cell lung cancer cells (NSCLC). *Oncogene*. **24**: 1412-1422
3. **Bren-Mattison Y**, Meyer A, Van Putten V, Li H, Moore M, Kuhn K, Stearman R, Winn RA, Heasley LE, and Nemenoff RA. (2008) Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-  $\gamma$  (PPAR- $\gamma$ ) in Non-Small Cell Lung Cancer Cells (NSCLC) are Mediated by Suppression of COX-2 via Inhibition of NF- $\kappa$ B. *Mol Pharmacol*. 73(3):709-717.

4. **Bren-Mattison Y**, Hausburg M, Olwin BB. (2011) Growth of Limb Muscle is Dependent on Skeletal-derived Indian Hedgehog. *Dev Biol.* 356(2):486-95.
5. Mattison CP, **Bren-Mattison Y**, Vant-Hull B, Vargas AM, Wasserman RL, Grimm CC. (2016) Heat-induced alterations in cashew allergen solubility and IgE binding. *Toxicol Rep.*3:244-251
6. Mattison CP, Grimm CC, Li Y, Chial HJ, McCaslin DR, Chung SY, **Bren-Mattison Y**, Wasserman RL. (2017) Identification and Characterization of Ana o 3 Modifications on Arginine-111 Residue in Heated Cashew Nuts. *J Agric Food Chem.* 65(2):411-420
7. Mattison CP, Khurana T, Tarver MR, Florane CB, Grimm CC, Pakala SB, Cottone CB, Riegel C, **Bren-Mattison Y**, Slater JE. (2017) Cross-reaction between Formosan termite (*Coptotermes formosanus*) proteins and cockroach allergens. *PLoS One.*12(8): e0182260
8. Mattison CP, Vant-Hull B, **Bren-Mattison Y**, Grimm CC. (2019) A cashew specific monoclonal antibody recognizing the small subunit of Ana o 3. *Toxicol Rep.*6:736-744.
9. Ramirez RA, Beyer DT, Oliva I, Voros B, Kokodis I, Thiagarajan R, Ricks MJ, **Bren-Mattison Y**, Boudreaux JP, Wang Y-Z, and Woltering EA. (2020) Liver Needle Biopsies Are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors. *Clinical Oncology and Research*. DOI: 10.31487/j.COR.2020.01.07
10. Jeha GM, Philip Boudreaux J, Woltering EA, **Bren-Mattison Y**, Thiagarajan R. Neuroendocrine Tumors of the Ampulla of Vater Treated with Local Resection. *Am Surg.* 2020 Nov;86(11):1575-1576. Epub 2020 Jul 30. PMID: 32731745.
11. Zhongqiang Li, Zheng Li, Qing Chen, Alexandra Ramos, Jian Zhang, J. Philip Boudreaux, Ramcharan Thiagarajan, **Yvette Bren-Mattison**, Michael E. Dunham, Andrew J. McWhorter, Xin Li, Ji-Ming Feng, Yanping Li, Shaomian Yao, Jian Xu. (2021) Detection of pancreatic cancer by convolutional-neural-network-assisted spontaneous Raman spectroscopy with critical feature visualization, *Neural Networks*, Volume 144, Pages 455-464, ISSN 0893-6080
12. Li Z, Li Z, Chen Q, Ramos A, Zhang J, Boudreaux JP, Thiagarajan R, **Bren-Mattison Y**, Dunham ME, McWhorter AJ, Li X, Feng JM, Li Y, Yao S, Xu J. Detection of pancreatic cancer by convolutional-neural-network-assisted spontaneous Raman spectroscopy with critical feature visualization. *Neural Network.* 2021 Dec;144: 455-464. doi: 10.1016/j.neunet.2021.09.006. Epub 2021 Sep 16. PMID: 34583101.

13. Landry J, **Bren-Mattison Y**, Ramirez R, Boudreaux JP, Woltering EA, Maluccio MA, and Ramcharan T (2020). Management of Appendiceal Neuroendocrine Tumors: Beyond Tumor Size. *J of Cancer Immunology. J Cancer Immunol.* 2020 volume2, issue 4.
14. Ramirez RA, Thomas K, Jacob A, Lin K, **Bren-Mattison Y**, Chauhan A. Adjuvant therapy for lung neuroendocrine neoplasms. *World J Clin Oncol.* 2021 Aug 24;12(8):664-674. PMID: 34513600; PMCID: PMC8394158.
15. Li Z, Li Z, Chen Q, Ramos A, Zhang J, Boudreaux JP, Thiagarajan R, **Bren-Mattison Y**, Dunham ME, McWhorter AJ, Li X, Feng JM, Li Y, Yao S, Xu J. Detection of pancreatic cancer by convolutional-neural-network-assisted spontaneous Raman spectroscopy with critical feature visualization. *Neural Network.* 2021 Dec; 144:455-464. doi: 10.1016/j.neunet.2021.09.006. Epub 2021 Sep 16. PMID: 34583101.
16. Li Z, Li Z, Ramos A, Boudreaux JP, Thiagarajan R, **Bren-Mattison Y**, Dunham ME, McWhorter AJ, Chen Q, Zhang J, Feng JM, Li Y, Yao S, Xu J. Detection of pancreatic cancer by indocyanine green-assisted fluorescence imaging in the first and second near-infrared windows. *Cancer Commun (Lond).* 2021 Dec;41(12):1431-1434. doi: 10.1002/cac2.12236. Epub 2021 Nov 17. PMID: 34787963; PMCID: PMC8696222.
17. Tao Xu, Joseph Dillon, **Yvette Bren-Mattison**, Mary A Maluccio, Nicholas J Skill, Dawn Quelle, Sarah Nash, Hyunkeun Cho4, Michael O'Rorke. Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers *Journal of Cancer Research and Clinical Oncology.* 2024. doi : 10.1007/s00432-024-06020-w
18. Skill NJ, Avanzino K, **Bren-Mattison Y**, Boudreaux JP, Thiagarajan R, Maluccio M. The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors. *J Gastrointest Cancer.* 2026 Jan 7;57(1):4. doi: 10.1007/s12029-025-01381-y. PMID: 41499067; PMCID: PMC12779679.

**Submitted and under review:**

1. **Yvette Bren-Mattison**, Mary A. Maluccio, Nicholas J. Skill, Katharine Thomas, Aman Chauhan, Donglin Yan, Maryann Wahmann, Robert Wahmann, Nithya Ramcharan, J. Philip Boudreaux, Ramcharan Thiagarajan, and Robert A. Ramirez. Telemedicine as a Countermeasure to Barriers Faced by Neuroendocrine Cancer Patients. *Endocrine-Related Cancer Journal.* Submitted
2. Mehrez J, Gentile B, Skill NJ, **Bren-Mattison Y**, Woltering EA and Maluccio MA. *Journal Frontiers in Oncology.* Black Raspberry Extract

Modulates Angiogenic Proteome Linked to Neuroendocrine Cancer.  
Submitted

3. Jace P. Landry, **Yvette B. Mattison**, Denise M. Danos, Brianne A. Voros, Robert A. Ramirez, J. Philip Boudreaux, Eugene A. Woltering, Ramcharan Thiagarajan, Mary A. Maluccio. Annals of Surgical Oncology. Metastatic Pancreatic Neuroendocrine Tumors at a Single Institution: The Role of Cytoreduction and the Clinical Factors Driving Outcomes. Submitted.

### **Non-refereed**

#### **Published:**

1. **Bren-Mattison Y.** (2015) p53 Mouse Models of Human Cancer. Nature Education 8(4):1.
2. Ramirez RA, **Bren-Mattison Y**, Thiagarajan R, Boudreaux JP, Marsala AJ, Ryan P, Maluccio MA (2020) Neuroendocrine tumor specialty center in New Orleans (NOLANETS) response to patient care during the COVID-19 pandemic. Oncologist. DOI: 10.1634/theoncologist.2020-0279. PMID: 32369669.

Yvette Bren-Mattison, PhD, H-Index 11, Google Scholar; H-Index 9, Scopus; and H-Index 9, Web of Science. Accessed on 03/27/2026

### **Book Chapters:**

1. Olwin, B.B., **Bren-Mattison, Y.**, Cornelison, D.D.W., Federov, Y.V., Flanagan-Steet, H. & Jones, N.C. Role of Cytokines in Skeletal Muscle Growth and Differentiation in Stem Cells and Cell Signaling in Skeletal Myogenesis, pp.97-126. Ed Sassoon, D.A. Advances in Developmental Biology and Biochemistry, Vol.11. Elsevier Press.

### **Invited Presentations**

#### **Local:**

March 2026 "Clinical Trials: Challenges and Advances in Neuroendocrine Research", CAGLA, New Orleans, LA

#### **Regional:**

May 2003 "Growth of Limb Muscle is Dependent on Skeletal-derived Indian Hedgehog", University of Wisconsin Madison

### **Scientific Presentations-Posters**

#### **Local/Regional:**

April 2025 “Appendiceal neuroendocrine tumor (ANET) post-surgical survival”. Farhan Mohiuddin, Nicholas J. Skill, **Yvette Bren-Mattison**, J. Philip Boudreaux, Ramcharan Thiagarajan, and Mary Maluccio. Louisiana American College of Surgeons Conference.

April 2025 “Histological analysis of resected neuroendocrine tumors to study low objective response rates to anti-angiogenics such as sunitinib”. Kenneth Avanzino, Nicholas J. Skill, **Yvette Bren-Mattison**, J. Philip Boudreaux, Ramcharan Thiagarajan, and Mary Maluccio. Louisiana American College of Surgeons Conference.

March 2026 “Gene sequencing reveals repeated mutations in mucin family of genes within gastrointestinal neuroendocrine neoplasms: WATSON STUDY. Nicholas Skill, J. Philip Boudreaux, Ramcharan Thiagarajan, **Yvette Bren-Mattison**, and Mary Maluccio. CAGLA Neaux Cancer Conference 2026

Predicting Response to Peptide Receptor Radiotherapy in Patients with Neuroendocrine Cancer using Metabolomics and Artificial Neural Networks. Graham Ball, Mary Maluccio, Daniel Raftery, **Yvette Bren-Mattison** and Nicholas Skill. CAGLA Neaux Cancer Conference 2026

Impact of lipophilic HMG-CoA-Reductase inhibitors on Somatostatin Receptor-2 (SSTR2) Peptide Receptor Radionucleotide Therapy (PRRT) for Neuroendocrine Neoplasms. Tala Maalouli, Farhan Mohiuddin, **Yvette Bren-Mattison**, Mary Maluccio, and Nicholas Skill. CAGLA Neaux Cancer Conference 2026

#### **National:**

October 2025 “Tobacco Cessation Improves Survival and Modulates Immune Profiles in Patients with Neuroendocrine Neoplasms. Farhan Mohiuddin, Nicholas Skill, Nupsius E Benjamin-Robinson, **Yvette Bren Mattison**, Mary Maluccio. American College of Surgeons 2025

May 2025 “Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) and Neuroendocrine Neoplasms”. Farhan Mohiuddin, **Yvette Bren-Mattison**, Mary Maluccio, and Nicholas Skill. Digestive Disease Week Conference 2025

#### **Grant Reviewer:**

2024–present North American Neuroendocrine Tumor Society – Scientific Review Committee

**Membership in Professional Organizations:**

|                |                                                                   |
|----------------|-------------------------------------------------------------------|
| 2019 – present | National Association of Neuroendocrine Tumor Specialists (NANETS) |
| 2020-present   | American Society of Clinical Oncology (ASCO)                      |
| 2022-present   | Association of Clinical Research Professionals (ACRP)             |
| 2023-present   | Society of Nuclear Medicine and Molecular Imaging                 |